Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy

Ban, Ga Young; Ye, Young-Min

doi:10.4168/aair.2023.15.1.1

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio of male to female participants with urticaria in this study was approximately 3:7, with a mean age of 33.45 ± 12.72 years (range 14-67 years). These findings are consistent with data from previous studies on the epidemiology of urticaria [23]. About 18% of our cohort suffered from prior allergic diseases, including allergic rhinitis, allergic asthma, and atopic dermatitis, which are known to be associated with urticaria.…”

Section: Discussionsupporting

confidence: 93%

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Yang,

Zou,

Cao

et al. 2023

COVID

View full text Add to dashboard Cite

The COVID-19 pandemic significantly disrupted global healthcare systems. The impacts of SARS-CoV-2 infection on urticaria and its management are unknown. This study aimed to collect information about patients with urticaria infected with SARS-CoV-2 and to investigate the impact of SARS-CoV-2 infection on urticaria severity, course, and treatment to better support recovery. This was a questionnaire-based study of patients with urticaria infected with SARS-CoV-2. Changes in urticaria severity (measured with the urticaria activity score (UAS)), course, and treatment were assessed before, during, and after SARS-CoV-2 infection. The mean (±SD) UAS scores were 5.17 ± 1.67, 4.23 ± 1.98, and 4.37 ± 1.93 before, during, and after SARS-CoV-2 infection, respectively (F = 8.839, p < 0.01). The median (IQR) wheal score was 0.464 (0.464, 0.763), 0.464 (0.138, 0.763), and 0.464 (0.138, 0.763) before, during, and after infection, respectively (Kruskal–Wallis H-test, H = 12.230, p = 0.02). The median (IQR) pruritus score was 0.695 (0.395, 0.695), 0.394 (0.123, 0.695), and 0.394 (0.123, 0.695) before, during, and after infection, respectively (Kruskal–Wallis H-test, H = 21.001, p < 0.01). Within the limitations of a questionnaire study, urticaria appears to improve during SARS-CoV-2 infection and worsens slightly after recovery, and the frequency of Western medicine use increases.

show abstract

Section: Discussionsupporting

confidence: 93%

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Yang,

Zou,

Cao

et al. 2023

COVID

View full text Add to dashboard Cite

show abstract

Exploring the content validity of the EQ-5D-5L and four bolt-ons (skin irritation, self-confidence, sleep, social relationships) in atopic dermatitis and chronic urticaria

Sussex,

Rencz,

Gaydon

et al. 2024

Qual Life Res

View full text Add to dashboard Cite

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Yang,

Zou,

Cao

et al. 2023

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic significantly disrupted global healthcare systems. The impacts of SARS-CoV-2 infection on urticaria and its management are unknown. To collect information about patients with urticaria infected with SARS-CoV-2 and to investigate the impact of SARS-CoV-2 infection on urticaria severity, course, and treatment to better support recovery. This was a questionnaire-based study of patients with urticaria infected with SARS-CoV-2. Changes in urticaria severity (measured with the urticaria activity score (UAS)), course, and treatment were assessed before, during, and after SARS-CoV-2 infection. Mean (± SD) UAS scores were 5.17 ± 1.67, 4.23 ± 1.98, and 4.37 ± 1.93 before, during, and after SARS-CoV-2 infection, respectively (F = 8.839, p < 0.01). The median (IQR) wheal score was 0.464 (0.464, 0.763), 0.464 (0.138, 0.763), and 0.464 (0.138, 0.763) before, during, and after infection, respectively (Kruskal-Wallis H-test, H=12.230, p = 0.02). The median (IQR) pruritus score was 0.695 (0.395, 0.695), 0.394 (0.123, 0.695), and 0.394 (0.123, 0.695) before, during, and after infection, respectively (Kruskal-Wallis H-test, H = 21.001, p < 0.01). Within the limitations of a questionnaire study, urticaria appears to improve during SARS-CoV-2 infection, worsens slightly after recovery, and the frequency of Western medicine use increases.

show abstract

Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy

Cited by 3 publications

References 15 publications

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Exploring the content validity of the EQ-5D-5L and four bolt-ons (skin irritation, self-confidence, sleep, social relationships) in atopic dermatitis and chronic urticaria

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Contact Info

Product

Resources

About